Laverock relocates to Tribeca development in London's Kings Cross, establishing expanded lab facilities to facilitate growth

• Laverock Therapeutics re-locates to LBIC to facilitate future growth, representing a key milestone for the company as it reports significant progress with its platform technologies, product pipeline and commercial offerings
• Fit-out complete, Laverock Therapeutics is the first company to take up occupation within LBIC’s new grow-on lab space at Tribeca London

LONDON, UK 17th March 2025:  London BioScience Innovation Centre (LBIC) is delighted to welcome Laverock Therapeutics (Laverock) to its new facility at the Apex Building, Tribeca London. The company has taken up occupation of its new 4,133 sq ft fully fitted lab and office space within this brand-new premium facility, located in the heart of the King’s Cross Knowledge Quarter. 

Complementing its existing facilities, LBIC’s new high-spec fitted lab and write up space within the Apex Building provides best in class grow-on space for innovative bioscience companies wishing to base themselves within this landmark waterside quarter and life sciences hub, whilst also facilitating growth for its existing clients. This expansion of LBIC’s innovation capability, which includes access to its comprehensive suite of scientific support services, designed to streamline the daily operations of commercial labs with access to essential equipment and research services, reaffirms its attractiveness as a world-leading destination for bioscience R&D in London. 

Laverock is a programmable advanced therapies company with a uniquely powerful gene silencing technology which allows the development of novel therapeutic approaches. Its technology harnesses the cell's natural gene regulatory mechanisms to develop a new generation of more effective, safer and accessible advanced therapies to tackle major diseases.



Laverock identified London and LBIC’s Apex facility as its preferred option for several reasons, including access to talent, the strong and evolving biotech community and proximity to world leading academic and translational centres. Establishing its long-term home in London has enabled Laverock to hire the highly skilled experimental and computational scientists required to drive its platform technologies and product portfolio forward. During its next phase of development, Laverock will push its lead candidates into pre-clinical development and further develop its commercial offerings and partnering pipeline.

The Apex is the first of four buildings to be delivered by the Reef Group as part of the wider Tribeca London development, London’s largest purpose-built life sciences development. This new destination sits at the intersection of life and science, ideally located in the heart of London’s exciting and fast-paced Knowledge Quarter. Blending cutting-edge science with modern city living, on completion the development will offer 600,000 sq ft of lab space at the centre of London’s biotech cluster, whilst directly connecting occupiers to a vibrant and diverse mix of culture, shopping and eateries alongside significant public realm.

Sustainability was also a key factor for Laverock when deciding where to locate. Tribeca London is committed to making a lasting positive contribution to community and environment with responsible decision-making central to every stage of the development. This commitment is evident within the BREEAM ‘Excellent’, all-electric, Apex Building, which has been ‘passive design’ optimised to limit heat loss and solar gain and maximise the use of natural light. Energy efficient LED lighting with automatic and smart control enabled electric systems are installed throughout and automated MEP controls incorporate smart reporting capability. Tribeca London is committed to Net-Zero Carbon in operation development with 100% renewable energy supply and annual offset of verified residual carbon.

Dr Rich Ferrie, CEO, LBIC commented: “We are thrilled to welcome Laverock to our facility at Apex and look forward to supporting the company’s growth as part of our expanding innovation ecosystem. Laverock’s gene silencing technology platform is well placed to enable the delivery of important new advanced therapies which will ultimately deliver significant patient benefit in the future. Our new Apex facility provides the ideal environment as Laverock drives the next phase of its development towards this hugely important aim.”

Tom Payne, COO, Laverock Therapeutics, said: “We are extremely excited to have completed our move into the Apex Building at Tribeca London, within the expanded London Bioscience Innovation Centre. This represents a major milestone for the company and comes alongside significant progress with our platform technologies and product pipeline.

“As part of the Knowledge Quarter, in London’s King’s Cross, the Tribeca development provides the best of all worlds – with great transport links, an aspirational work environment, and close proximity to world class academic and translational centres, making it the leading hub for life sciences companies in Europe. 

“When reviewing potential developments in London, the bespoke nature of the support for early stage biotechs delivered by the experienced LBIC team really stood out to us. LBIC has supported us throughout this transition, enabling us to focus on our scientific and commercial objectives.” 

- ENDS -

Contact: LBIC

Sarah Brereton, Director, Limewash
Tel: +44 (0)7796 583 223
Email: sarah@limewash.co.uk

Contact: Laverock

Email: contact@laverocktx.com

Additional Material

Headshots of all quoted and images of the Apex Building are available to download here: https://we.tl/t-9OfCjowYPX

Notes to Editors:

About LBIC

Founded in 2000, LBIC (London BioScience Innovation Centre), London’s first bio-incubator has been a key enabler of biomedical innovation for over two decades.

As a wholly owned subsidiary of the Royal Veterinary College - the UK’s largest and longest established independent veterinary school and world-class research-led institution - LBIC is committed to nurturing the growth of life science companies and supporting advances in bioscience research and development.

LBIC provides state-of-the-art laboratory facilities, office spaces, and virtual support services, hosts engaging events and facilitates peer-to-peer networking opportunities. It is home to a community of more than 60 life science companies, ranging from innovative startups to multinational corporations.

Located in London’s vibrant Knowledge Quarter, just a ten-minute walk from King’s Cross and St Pancras International stations, LBIC offers excellent access to both domestic and international transport links.

For more details, visit lbic.com. 

About Laverock Therapeutics

Laverock Therapeutics is a gene-silencing company with a uniquely powerful technology which harnesses the cell’s natural gene regulatory mechanisms to develop a new generation of programmable advanced therapies to tackle major diseases. Laverock’s truly innovative technology re-directs naturally-occurring micro RNAs (miRNAs) to conditionally silence genes in a way which is programmable, tunable, stable and specific. This opens a path to more effective, safer and accessible advanced therapies. Laverock is applying its technology through its own pipeline – targeting regenerative medicine and oncology – and through partnerships.

Laverock has a highly experienced leadership team with proven track records in biotechnology, pharma and academia and an exceptionally strong Board. Laverock has raised £13.5m seed funding to date from high-calibre investors including Calculus Capital, Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos, UK Innovation & Science Seed Fund and Tekfen Ventures.

For more information, please visit www.laverocktx.com and follow us on LinkedIn.